Non-Hodgkin Lymphoma | Tumor

Third Full Dose of COVID-19 Vaccine Increases Antibody Response in Patients with Blood Cancers

December 23rd 2021

New findings show that 43% of patients with certain blood cancers produced COVID-19 antibodies after receiving a third full dose of the mRNA vaccine.

When Faced With Death, Live Life to the Fullest, Says a Cancer Survivor

December 21st 2021

“I had to choose one of two paths, to become the victim and let the disease control me or take control of the disease and fight for my life. The moment I chose to fight was the moment life opened all of its beauty,” writes a lymphoma survivor.

Cancer Is a Wilderness That Gives Us a Choice: Panic or Trust

December 17th 2021

A non-Hodgkin’s lymphoma survivor writes about how she chose to approach a stressful doctor’s appointment and how doing whatever helps may look different for everyone.

Cancer Clinical Trial Enrollment Is Low in the US, and Patient Depression and Anxiety May Play a Role

December 12th 2021

Researchers found that depression and anxiety may skew patient perceptions of participating in blood cancer clinical trials, thus contributing to low enrollment throughout the United States.

Expansion of IOA-244 Trial Fully Enrolled for Uveal Melanoma

November 26th 2021

Part B of the DIONE-01 study will look at whether IOA-244 increases anti-tumor responses in expansion groups of patients.

Assessing Both Sides of the Argument for In-Home Cancer Infusions

November 18th 2021

Although the interest of at-home care including the administration of cancer infusions has grown since the start of the COVID-19 pandemic, hesitation looms over its convenience, cost and safety.

FDA Will Review New Drug to Treat Non-Hodgkin Lymphoma

November 1st 2021

The Food and Drug Administration will review parsaclisib for the treatment of patients with follicular lymphoma, marginal zone lymphoma and mantle cell lymphoma.

It Takes a Village: Cancer Caregivers Need to Care for Themselves, Too

October 7th 2021

Caregivers of patients with cancer may face financial toxicity and stress — with little time to take care of themselves.

Age, Other Health Factors Can Play a Role in Cancer Treatment Decisions

September 23rd 2021

The prescription of systemic cancer therapies varies based on a patient’s age, comorbidities, cancer stage and other variables, according to recent research.

FDA Approval of Brukinsa in Rare Lymphoma Offers a New Option, Though Will Not Replace Other Therapies

September 22nd 2021

The FDA approval of Brukinsa represents another treatment option with fewer side effects in patients with Waldenstrom's macroglobulinema, however it will not serve as a replacement for other therapies.

Brukinsa Receives FDA Approval for Treatment of Waldenstrom’s Macroglobulinemia

September 1st 2021

The FDA approval of Brukinsa, according to an expert from the Dana-Farber Cancer Institute, provides an important new option for targeted therapy in Waldenstrom’s macroglobulinemia.

Survivor Turns Negative Thoughts Into Laughable Moments During Cancer Treatment

August 6th 2021

A survivor shares how she chose to approach her mindset during cancer treatments to keep herself from spiraling.

Roundup Herbicide Will Ditch Glyphosate, the Chemical Linked to Cancer

July 29th 2021

Bayer, the manufacturer of Roundup, created a five-point plan to decrease the risk of facing future litigation about its product causing cancer.

Patients With Blood Cancer Less Likely to Produce COVID-19 Antibodies After Vaccination

July 26th 2021

About 25% of patients with blood cancer did not produce antibodies after being vaccinated against COVID-19.

Pistol Annies’ Singer Ashley Monroe Shares Cancer Diagnosis, Cancer Survivor Breaks Weightlifting Records, And More

July 16th 2021

From Ashley Monroe’s blood cancer diagnosis to a CrossFit athlete’s inspiring cancer journey, here’s what’s happening in the cancer landscape this week.

How Do You Get Back to a ‘Normal Life’ After Cancer?

July 9th 2021

Do you keep your job? Your friends? One cancer survivor discusses her decisions after being told her non-Hodgkin lymphoma was in remission.

Turning Chemotherapy Into Comedy

July 8th 2021

In this episode of the “CURE® Talks Cancer” podcast, a cancer survivor explains how she took a lighthearted and comedic approach to her cancer treatment process and went on to create a coloring book based on the funny thoughts she had.

Novel Combo Therapy Shows Promise in Certain Patients With Non-Hodgkin Lymphoma

June 6th 2021

Treatment with a novel combination therapy was associated with increased efficacy among patients with aggressive relapsed or refractory B-cell non-Hodgkin lymphoma and was also well tolerated.

FDA Approves Xalkori for Children, Young Adults With Relapsed or Refractory Anaplastic Large Cell Lymphoma

January 14th 2021

The Food and Drug Administration approved the supplemental new drug application for Xalkori (crizotinib) to treat children and young adults between the ages of 1 and 21 with relapsed or refractory, systemic ALK-positive anaplastic large cell lymphoma.

CAR-T Cell Therapy Product for Relapsed/Refractory Large B-Cell Lymphoma Still Under FDA Review

January 6th 2021

The FDA has not yet reached a decision on an application for the approval of a CAR-T cell therapy product for the treatment of relapsed/refractory large b-cell lymphoma and, according to Bristol Myers Squibb, a new action date for the decision has not been set.

Friday Frontline: Black Patients with Cancer at Higher Risk for COVID-19 Infections, Colts Punter Looks to Play Again After Successful Cancer Surgery and More

December 18th 2020

From a new study showing data that patients with cancer, especially Black patients with cancer, are at a higher risk for COVID-19 than non-cancer patients to NFL punter Rigoberto Sanchez making a speedy recovery after surgery for cancer, here’s what’s happening in the cancer space this week.

FDA Approves Rituxan Biosimilar, Riabni, For Patients with Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Two Blood Vessel Disorders

December 17th 2020

For multiple patients with blood cancers who would normally use Rituxan, the Food and Drug Administration has approved the biosimilar Riabni based off highly similar clinical evidence between the two drugs, potentially lowering costs for patients.

Treating Waldenstrom’s Macroglobulinemia

December 17th 2020

In this episode of the “CURE Talks Cancer” podcast, we spoke with Dr. Asher Chanan-Khan about current standards of care for Waldenstrom macroglobulinemia, as well as a clinical trial looking at a novel therapy.

Long-Term Data of Imbruvica-Rituxan Combo in Waldenstrom’s Macroglobulinemia Demonstrates ‘Major Step Forward’

December 8th 2020

In an interview with CURE®, a Waldenstrom’s macroglobulinemia expert discusses the long-term benefits of the targeted combination of Imbruvica and Rituxan.

Treatment with Imbruvica and Rituxan May Benefit Patients with Waldenstrom’s Macroglobulinemia Out to 5 Years

December 6th 2020

The benefit observed in patients with Waldenstrom’s macroglobulinemia treated with Imbruvica (ibrutinib) plus Rituxan (rituximab), compared with placebo and Rituxan, focused on survival and response to the treatment, both of which occurred despite prior treatment and genotypes.

Kymriah Safely Treats ALL and NHL in Real-World Setting

December 2nd 2020

Safety and efficacy observed in this real-world study for patients with non-Hodgkin lymphoma similarly reflect findings from previous pivotal trials.

A Look Back at the Beginnings of CAR-T Cell Therapy

December 2nd 2020

A novel type of immunotherapy known as chimeric antigen receptor, or CAR, T cell therapy is a hot topic in the news and in the lab. But what does this treatment consist of, and how was it developed?

A Journey Through DLBCL: Cautiously Hopeful

November 25th 2020

Managing DLBCL: A Team Effort

November 25th 2020

CAR-T for Relapsed DLBCL: Advice for Patients & Caregivers

November 25th 2020